NCT04196764

Brief Summary

Prospective observational study of 6 months of follow-up, of national and multicenter scope with medical device with CE marking and according to the usual clinical practice. In addition, due to the observational design of the clinical investigation, no assignment of the patients will be made to any specific study group, but will be carried out in accordance with the usual clinical practice, not applying any intervention other than the usual one in this type of care practice and always in accordance with current clinical guidelines and recommendations and with the indications authorized in Spain. Patients will be recruited by specialists and will be followed for 6 months under the conditions of usual clinical practice.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
188

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2017

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 28, 2017

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 21, 2019

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 21, 2019

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

December 11, 2019

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 12, 2019

Completed
Last Updated

February 21, 2021

Status Verified

December 1, 2019

Enrollment Period

1.7 years

First QC Date

December 11, 2019

Last Update Submit

February 18, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • evolution of pain in patients diagnosed with primary knee osteoarthritis 3 months after being treated with hyaluronic acid

    3-month baseline change in the domain A score of the WOMAC questionnaire pain will be analyzed to evaluate pain evolution.

    3 months

Secondary Outcomes (8)

  • evolution of pain in patients diagnosed with primary knee osteoarthritis during the study

    15 days, 1 and 6 months

  • Pain evolution in motion

    15 days, 1, 3 and 6 months

  • stiffness evolution

    15 days, 1, 3 and 6 months

  • evolution of the patient's functional capacity

    15 days, 1, 3 and 6 months

  • evolution of the patient's quality of life

    3 months

  • +3 more secondary outcomes

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study population will be made up of subjects of legal age diagnosed with primary knee osteoarthritis who have pain equal to or greater than 4 measured by VAS. All patients included in this clinical investigation must have been duly informed by the investigator about the investigation procedure and its objectives.

You may qualify if:

  • Patients of both sexes and over 18 years.
  • Patients with a previous diagnosis of primary knee osteoarthritis according to ACR criteria and who have a knee x-ray performed during the previous 18 months.
  • Patients who attend a control clinic for primary osteoarthritis of symptomatic knee.
  • Patients with pain equal to or greater than 4 on the VAS scale.
  • Patients who have been prescribed an injection of Pronolis® HD as part of the usual clinical practice.
  • Patients who have given their written informed consent to participate in the clinical investigation.
  • Patients for whom there is a reasonable expectation of follow-up during the development of clinical research.
  • Patients who understand and can complete the questionnaires and do not have cognitive impairment that prevents it.

You may not qualify if:

  • Patients with known intolerance to hyaluronic acid.
  • Patients with hypersensitivity to intraarticular injections.
  • Patients who present with infection in the knee joint.
  • Patients presenting with a skin disorder or infection in the area of injection or systemic.
  • Coagulation disorders that contraindicate puncture.
  • Patients who have been prescribed intra-articular injection in both knees.
  • Patients diagnosed with autoimmune rheumatologic diseases or connective diseases.
  • Patients diagnosed with microcrystalline diseases.
  • Patients with traumatic history in the study joint.
  • Patients with a surgical history in the study joint.
  • Pregnant or breastfeeding women.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital del Mar

Barcelona, 08003, Spain

Location

Related Publications (1)

  • Calvet J, Khorsandi D, Tio L, Monfort J. Evaluation of a single-shot of a high-density viscoelastic solution of hyaluronic acid in patients with symptomatic primary knee osteoarthritis: the no-dolor study. BMC Musculoskelet Disord. 2022 May 11;23(1):442. doi: 10.1186/s12891-022-05383-w.

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 11, 2019

First Posted

December 12, 2019

Study Start

May 28, 2017

Primary Completion

February 21, 2019

Study Completion

October 21, 2019

Last Updated

February 21, 2021

Record last verified: 2019-12

Locations